Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO3 responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial.
Saved in:
| Title: | Genomic investigation and clinical correlates of the in vitro β-lactam: NaHCO |
|---|---|
| Authors: | Petersiel N; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Giulieri S; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Daniel DS; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Fan S-H; The Lundquist Institute for Biomedical Innovation, Torrance, California, USA., Ersoy SC; The Lundquist Institute for Biomedical Innovation, Torrance, California, USA., Davis JS; Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.; Department of Infectious Diseases, John Hunter Hospital, Newcastle, New South Wales, Australia., Bayer AS; The Lundquist Institute for Biomedical Innovation, Torrance, California, USA.; The Geffen School of Medicine, University of California, Los Angeles, California, USA., Howden BP; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Centre for Pathogen Genomics, The University of Melbourne, Melbourne, Victoria, Australia.; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia., Tong SYC; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. |
| Corporate Authors: | CAMERA2 study group |
| Source: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Jul 09; Vol. 68 (7), pp. e0021824. Date of Electronic Publication: 2024 Jun 05. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
